ACC slides: Cardiac troponin can measure risk in ischemic heart disease

Editorial Staff | March 14, 2013 | Cardiovascular Business | Structural Heart Disease

SAN FRANCISCO—Serial measurements of cardiac troponin using an investigational high-sensitivity assay enhanced risk stratification for cardiovascular disease and heart failure in patients with stable ischemic heart disease, according to an analysis of the PROVE IT-TIMI 22 study, presented March 9 at the American College of Cardiology’s (ACC) scientific session.

Cardiac troponin is an emerging prognostic biomarker in patients with stable ischemic heart disease. In this study, lead investigator Ryan G. O'Malley, MD, of Brigham and Women's Hospital in Boston, and colleagues assessed the prognostic performance of serial measurements of an investigational high-sensitivity cardiac troponin assay in patients with stable ischemic heart disease.

ACC slides: Cardiac troponin can measure risk in ischemic heart disease from trimedmedia

About the lead author:

Dr. O'Malley is in the internal medicine/adult primary care department of Brigham and Women's Hospital in Boston.

Editorial Staff

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business

Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Related Content

Around the web